Manages elevated serum phosphorus levels. ANDA 90978, held by Natco Pharma Ltd. Lanthanum Carbonate.
As of Nov 16, 2026, ANDA 90978 (Lanthanum Carbonate), held by Natco Pharma Ltd, was first approved by FDA on Aug 11, 2017, with 2 approved supplements and 0 published complete response letters.
Lanthanum carbonate chewable tablet is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2017 | Original application | Approved | None posted |
| Lanthanum CarbonateEQ 500MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 750MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 1GM BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Jul 20, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 20, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters